38275-57-9

Usage

Uses

Used in Organic Synthesis:
5-Bromopyrimidine-2-carbonitrile is used as a key intermediate for the synthesis of various organic compounds. Its unique chemical structure allows for the creation of a wide range of molecules with diverse applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Bromopyrimidine-2-carbonitrile is utilized as a vital building block for the development of new drugs. Its properties make it suitable for the synthesis of therapeutic agents targeting various medical conditions.
Used in Agrochemicals:
5-Bromopyrimidine-2-carbonitrile is also employed in the agrochemical sector as a starting material for the production of pesticides, herbicides, and other agricultural chemicals. Its incorporation into these products helps improve their effectiveness and efficiency in protecting crops and enhancing agricultural yields.

InChI:InChI=1/C5H2BrN3/c6-4-2-8-5(1-7)9-3-4/h2-3H

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 36529-69-8 5-bromopyrimidine N-oxide 
• 143-33-9 sodium cyanide 
• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 773837-37-9 sodium cyanide 

Downstream Products

• 1189169-37-6 1-(5-bromopyrimidin-2-yl)ethan-1-one 
• 1454252-62-0 [5-(phenylsulfanyl)pyrimidin-2-yl]methanamine 
• 1454252-63-1 tert-butyl N-[[5-(phenylsulfanyl)pyrimidin-2-yl]methyl]carbamate 
• 1454252-64-2 tert-butyl N-[[5-(benzenesulfonyl)pyrimidin-2-yl]methyl]carbamate 
• 1454252-65-3 [5-(benzenesulfonyl)pyrimidin-2-yl]methanamine 
• 1454250-76-0 imidazo[1,2-a]pyridine-6-carboxylic acid (5-benzenesulfonyl-pyrimidin-2-ylmethyl)-amide 
• 1454252-61-9 5-(phenylsulfanyl)pyrimidin-2-carbonitrile 
• 1013335-78-8 5-bromopyridine-2-carboxylic acid chloride 
• 915948-91-3 (S)-3-{[2-(azetidin-1-ylcarbonyl)pyrimidin-5-yl]oxy}-5-[(1S)-2-methoxy-1-methylethoxy]benzoic acid 
• 1454250-79-3 furo[2,3-c]pyridine-2-carboxylic acid (5-benzenesulfonyl-pyrimidin-2-ylmethyl)-amide 

Relevant academic research and scientific papers

Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility

Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likely source of the TDI signal, and replacement with other bicyclic systems was found to reduce or eliminate the TDI finding. A strategy of reducing the number of aromatic rings and/or lowering c Log D7.4 was then employed to significantly improve aqueous solubility. These efforts culminated in the discovery of 42, a compound with no evidence of TDI, improved aqueous solubility, and robust efficacy in tumor xenograft studies.

Cyclic Amines

The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.

PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES

Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.

Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA Desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome

Stearoyl-CoA desaturase-1 (SCD1) catalyzes de novo synthesis of monounsaturated fatty acids from saturated fatty acids. Studies have demonstrated that rodents lacking a functional SCD1 gene have an improved metabolic profile, including reduced weight gain, lower triglycerides, and improved insulin response. In this study, we discovered a series of piperazinylpyridazine-based highly potent, selective, and orally bioavailable compounds. Particularly, compound 49 (XEN103) was highly active in vitro (mSCD1 IC50 = 14 nM and HepG2 IC50 = 12 nM) and efficacious in vivo (ED50 = 0.8 mg/kg). It also demonstrated striking reduction of weight gain in a rodent model. Our findings with small-molecule SCD1 inhibitors confirm the importance of this target in metabolic regulation, describe novel models for assessing SCD1 inhibitors for efficacy and tolerability and demonstrate an opportunity to develop a novel therapy for metabolic disease.

2-ALKYNYL-6-PYRIDIN-2-YL-PYRIDAZINONES, 2-ALKYNYL-6-PYRIDIN-2-YL-DIHYDROPYRIDAZINONES, 2-ALKYNYL-6-PYRIMIDIN-2-YL-PYRIDAZINONES AND 2-ALKYNYL-6-PYRIMIDIN-2-YL-DIHYDROPYRIDAZINONES AND THEIR USE AS FUNGICIDES

This invention relates to certain novel 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and to the use of these compounds for control of fungal pathogens of plants and mammals.

PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS

This invention is directed to a compound wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or

HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R12 is a hydroxylated alkyl group and R9 contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.

SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS

The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing, said, inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).

BENZO ‘ D!AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

The present invention relates to benzazepine derivatives of formula ( I ) wherein: R1 represents -C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

Studies on Pyrimidine Derivatives. XXXIX. Site-Selectivity in the Reaction of 5-Substituted and 4,5-Disubstituted Pyrimidine N-Oxides with Trimethylsilyl Cynanide

The site-selectivity in the modified Reissert-Henze reaction of 5-substituted and 4,5-disubstituted pyrimidine 1-oxides with trimethylsilyl cyanide was examined.The reaction of 5-substituted 4-methoxypyrimidine 1-oxides with trimethylsilyl cyanide gave exclusively 2-pyrimidinecarbonitriles in good yields without exception.On the other hand, the other 5-substituted and 4,5-disubstituted pyrimidine 1-oxides gave mainly 6-pyrimidinecarbonitriles.Keywords--site-selectivity; pyrimidine N-oxide; trimethylsilyl cyanide; Reissert-Henze reasction; pyrimidinecarbonitrile